Harvard Bioscience, Inc. (NASDAQ:HBIO) reported an EPS of $0.0004, missing the estimated $0.07, but surpassed revenue expectations with $24.56 million.
The company experienced a sequential increase in pre-clinical revenues across all regions, despite a slight decline in revenues from cellular and molecular technology due to reduced purchasing by US academic customers.
Despite a negative P/E ratio of -2.41, HBIO’s price-to-sales ratio of 0.32 and enterprise value to sales ratio of 0.27 suggest a valuation discrepancy, with a challenging current ratio of 0.82.
Harvard Bioscience, Inc. (NASDAQ:HBIO) is a global developer, manufacturer, and marketer of a broad range of solutions to advance life science research and regenerative medicine. The company focuses on providing innovative products for pre-clinical research, cellular and molecular technology, and other scientific applications. HBIO competes with other life science companies in delivering cutting-edge research tools.
On March 12, 2025, HBIO reported its earnings, revealing an earnings per share (EPS) of $0.0004, which was below the estimated $0.07. Despite this, the company achieved revenue of $24.56 million, surpassing the expected $22.95 million. This revenue growth was driven by a sequential increase in pre-clinical revenues across all regions, as highlighted by Jim Green, the Chairman and CEO.
During the Fourth Quarter 2024 Earnings Conference Call, attended by analysts like Paul Knight from KeyBanc and Bruce Jackson from The Benchmark Company, HBIO discussed its financial performance. The company noted a slight decline in revenues from cellular and molecular technology (CMT) due to reduced purchasing by US academic customers. However, the strong market reception of new products, such as the SoHo™ telemetry systems and MeshMEA™ organoid systems, provides optimism for future growth.
HBIO’s price-to-sales ratio of 0.32 suggests that the stock is valued at 32 cents for every dollar of sales. The enterprise value to sales ratio of 0.27 reflects the company’s valuation relative to its revenue. However, the enterprise value to operating cash flow ratio of 17.90 indicates that the operating cash flow can cover the enterprise value multiple times.
Additionally, the current ratio of 0.82 suggests that HBIO may face challenges in covering its short-term liabilities with its short-term assets. Despite these financial hurdles, the company’s focus on innovative products and market expansion remains a key strategy for future growth.
